688289 圣湘生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,244,13920.49%1,458,0621,007,1196,450,3574,514,539
减:营业总成本1,066,90920.12%1,278,341981,8413,908,2931,982,677
    其中:营业成本336,21644.72%322,055286,6412,655,3681,279,045
               财务费用(49,321)-18.16%(85,287)(53,454)(50,363)11,549
               资产减值损失10,779-31.01%43,8327,507(268,846)(12)
公允价值变动收益47,983545.10%8,40861,84399,13686,132
投资收益(38,755)35.44%(28,844)253,737(19,896)(5,120)
    其中:对联营企业和合营企业的投资收益(40,501)49.56%(31,894)(22,158)(19,994)(6,005)
营业利润197,307-5.43%277,777427,4632,339,8092,621,786
利润总额179,774-10.21%260,611410,4782,315,9222,616,205
减:所得税费用17,798-52.06%34,33862,311379,215373,682
净利润161,976-0.68%226,273348,1671,936,7072,242,524
减:非控股权益(29,345)-9.29%(49,323)(15,554)(94)(173)
股东净利润191,321-2.10%275,596363,7211,936,8012,242,696

市场价值指针
每股收益 (元) *0.330-2.94%0.4700.6203.3103.810
每股派息 (元) *0.2624.80%0.5250.4621.2981.125
每股净资产 (元) *12.307-0.80%12.43712.23712.74615.922
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容